No Data
Huaxi Biotech 2025 First Quarter Report
Express News | Bloomage Biotechnology Q1 Net Profit Down 58.1% Y/Y
Bloomage Biotechnology Corporation Limited (688363.SH): Revenue from the USA market has not yet reached 3% of the company's total revenue.
According to a statement on April 16 from Bloomage Biotechnology Corporation Limited (688363.SH) on the interactive platform, the revenue from the USA market has not yet reached 3% of the company's total revenue, and the impact of tariff adjustments on the company's direct performance is limited. The company is a globally renowned biotechnology company driven by synthetic biotechnology innovation, as well as a full Industry Chain platform for biomaterials. It is also one of the largest producers and sellers of hyaluronic acid in the world. The company relies on significant investment in Assets and advantages from scaled costs, which has formed a strong customer loyalty, and the market foundation is stable. In the medium to long term, there is still uncertainty in tariff policies, and the company will continue to closely monitor the developments in tariff policies.
Bloomage Biotechnology Corporation Limited (688363.SH): mainly uses DeepSeek and self-developed AI applications primarily applied in the fields of branding, marketing, research and development, supply chain, procurement, and other Business areas.
On April 16, Gelonghui reported that Bloomage Biotechnology Corporation Limited (688363.SH) announced on the interactive platform that the company accessed DeepSeek's official API on February 7, 2025, and localized the deployment of the DeepSeek-R1 32b version model. Subsequently, the company also integrated the full-version DeepSeek from other third-party platforms as a supplement. On February 24, 2025, the upgraded version of the DeepSeek model and related AI applications was officially released along with the iterative plan of the company's internal AI application integration platform. In terms of applications, the company primarily uses DeepSeek and
Huaxi Biotech: Huaxi Biotech 2024 Annual Report Summary
Huaxi Biotech: Huaxi Biotech 2024 Annual Report
Bloomage BioTechnology Corporation Limited's (SHSE:688363) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
